Livewire Exclusive

Catherine Wood, CEO and CIO at ARK Investment Management (ARK), invests on the cutting edge of robotics, energy storage, next-generation internet and blockchain technology. However it is in the field of genomic sequencing that she tell us: “Something is happening that is more profound than I’ve ever experienced”.

Key points

  • A revolutionary gene-editing technology has emerged that may potentially hold the cure for some diseases. The first human trials in the US are taking place this year in cases of paediatric blindness.
  • Another technology that ARK is backing can turn a patient’s immune system against cancerous cells. It is yielding promising results in non-Hodgkin’s lymphoma.

Further insights

Nikko AM Australia is pleased to bring the ARK Investment Management strategies and capabilities to Australia. Click here to find out more

ARK Investment Management is a Nikko Asset Management strategic partner. This material is issued in Australia by Nikko AM Limited ABN 99 003 376 252, AFSL 237563.


Comments

Please sign in to comment on this wire.